MAI Capital Management decreased its stake in Sanofi (NASDAQ:SNY – Free Report) by 38.2% during the 3rd quarter, ...

The top spenders in the space, however, are Sanofi and Regeneron. The companies marketed Dupixent (dupilumab), a biologic ...

Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

Best Genomics Stocks To Buy Right Now. Genomics is the study of genes and how they function. Many rapidly growing companies ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Zacks Research increased their FY2024 EPS estimates for shares of Sanofi in a report issued on Wednesday, November 13th.

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.